The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
BCKDHB (branched-chain keto acid dehydrogenase E1 subunit beta) encodes the beta subunit of the E1 component of the mitochondrial branched-chain alpha-ketoacid dehydrogenase (BCKDH) complex. The protein is also designated 2-oxoisovalerate dehydrogenase subunit beta (EC 1.2.4.4). The gene maps to chromosome 6 in humans and its product is synthesized as a precursor with a mitochondrial targeting sequence that is cleaved upon import (ævarsson2000crystalstructureof pages 1-2, billington2022genomicandbiochemical pages 1-3). The mature beta subunit comprises 342 residues with a molecular mass of approximately 37.8 kDa (ævarsson2000crystalstructureof pages 1-2).
The following table summarizes the key molecular properties of BCKDHB:
| Gene name | UniProt ID | Protein name | Organism | EC number | Molecular weight | Structure | Cofactors | Substrates | Products | Subcellular localization | Key domains | Disease association | Regulatory mechanism |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCKDHB | P21953 | Branched-chain alpha-keto acid dehydrogenase E1 component beta chain; 2-oxoisovalerate dehydrogenase subunit beta, mitochondrial | Homo sapiens | EC 1.2.4.4 | E1β subunit ~37.8 kDa; E1 complex contains two 37.8 kDa β subunits plus two 45.5 kDa α subunits (ævarsson2000crystalstructureof pages 1-2) | α2β2 heterotetramer within the E1 component of the BCKDH complex; active sites formed at α–β′ interfaces (ævarsson2000crystalstructureof pages 1-2, ævarsson2000crystalstructureof pages 7-8, ævarsson2000crystalstructureof pages 2-4) | ThDP/TPP; K+ stabilizing site in β subunit (ævarsson2000crystalstructureof pages 1-2, ævarsson2000crystalstructureof pages 2-4, ævarsson2000crystalstructureof pages 4-5) | Branched-chain α-ketoacids: KIC (2-oxoisocaproate, from leucine), KMV (2-oxo-3-methylvalerate, from isoleucine), KIV (2-oxoisovalerate, from valine) (billington2022genomicandbiochemical pages 1-3, du2022theroleof pages 1-2) | Corresponding branched-chain acyl-CoAs after oxidative decarboxylation: isovaleryl-CoA, α-methylbutyryl-CoA, isobutyryl-CoA + CO2 (via transfer to lipoyl-E2 during the BCKDH reaction) (billington2022genomicandbiochemical pages 1-3, du2022theroleof pages 1-2) | Primarily mitochondrial matrix as part of the BCKDH complex; recent cardiac evidence also supports an extramitochondrial/ER-associated pool (du2022theroleof pages 2-4, ogawa2023downregulationofextramitochondrial pages 11-13, ogawa2023downregulationofextramitochondrial pages 9-11, weiss2024mitolnccontrolscardiac pages 10-12) | THDP-binding and transketolase-like domains; β subunit contributes residues required for cofactor binding, metal coordination, and E2 interaction (ævarsson2000crystalstructureof pages 2-4, ævarsson2000crystalstructureof pages 10-12) | Maple syrup urine disease (MSUD) type 1B caused by pathogenic BCKDHB variants; major disease gene in multiple population studies (margutti2020maplesyrupurine pages 2-4, campanholi2021molecularbasisof pages 1-2, rodriguezpombo2006mutationalspectrumof pages 1-3, OpenTargets Search: -BCKDHB) | BCKDH complex is inhibited by BCKDK-mediated phosphorylation of the E1α subunit and activated by PPM1K/PP2Cm-mediated dephosphorylation; BCKAs such as KIC allosterically suppress BCKDK (huang2025branchedchainaminoacids pages 13-14, du2022theroleof pages 2-4, du2022theroleof pages 6-7) |
Table: This table summarizes core molecular, biochemical, structural, localization, and disease-related properties of human BCKDHB. It is useful as a compact reference for functional annotation of the BCKDHB gene product within the BCKDH complex.
BCKDHB functions exclusively as part of the BCKDH multienzyme complex, which catalyzes the irreversible oxidative decarboxylation of the three branched-chain alpha-ketoacids (BCKAs) derived from the essential branched-chain amino acids (BCAAs) leucine, isoleucine, and valine. This represents the rate-limiting and committed step in the BCAA catabolic pathway (mei2026branchedchainaminoacids pages 3-5, huang2025branchedchainaminoacids pages 4-5).
The E1 component, composed of BCKDHA (alpha subunit) and BCKDHB (beta subunit) as an α₂β₂ heterotetramer, is a thiamine diphosphate (ThDP)-dependent decarboxylase (du2022theroleof pages 1-2, ævarsson2000crystalstructureof pages 1-2). The three substrates and their products are:
In the reaction mechanism, the alpha-keto acid first binds to ThDP and is decarboxylated by E1. The resulting branched-chain acyl group is then oxidatively transferred to the lipoyl domain of the E2 (dihydrolipoamide branched-chain transacylase, encoded by DBT) subunit, which subsequently catalyzes transacylation to coenzyme A. E3 (dihydrolipoamide dehydrogenase, encoded by DLD) reoxidizes the reduced lipoyl groups and regenerates NAD⁺ (billington2022genomicandbiochemical pages 1-3, du2022theroleof pages 1-2). The resulting branched-chain acyl-CoAs are subsequently metabolized through pathways analogous to fatty acid β-oxidation, ultimately producing acetyl-CoA and succinyl-CoA for entry into the TCA cycle (mei2026branchedchainaminoacids pages 3-5, du2022theroleof pages 2-4).
The complete composition of the BCKDH complex is summarized below:
| Component | Gene(s) | Subunit structure | Function in the complex | Key features |
|---|---|---|---|---|
| E1 | BCKDHA, BCKDHB | α2β2 heterotetramer | ThDP-dependent oxidative decarboxylation of branched-chain α-ketoacids (KIC, KMV, KIV); initiates transfer of the acyl group to the lipoyl domain of E2 | Active sites lie at α–β′ interfaces; human structure solved at 2.7 Å; β subunit contributes to ThDP binding, K+ coordination, and E2 interaction (billington2022genomicandbiochemical pages 1-3, ævarsson2000crystalstructureof pages 1-2, ævarsson2000crystalstructureof pages 7-8, ævarsson2000crystalstructureof pages 2-4, ævarsson2000crystalstructureof pages 4-5) |
| E2 | DBT | 24-mer core (branched-chain dihydrolipoamide acyltransferase scaffold) | Accepts the branched-chain acyl group from E1 via its lipoyl domain and catalyzes transacylation to CoA, forming branched-chain acyl-CoAs | Central architectural scaffold of the BCKDH complex; lipoyl domain shuttles reaction intermediates between active sites (billington2022genomicandbiochemical pages 1-3, he2026bcaasandrelated pages 8-10) |
| E3 | DLD | Homodimeric dihydrolipoamide dehydrogenase shared among multiple 2-oxoacid dehydrogenase complexes | Reoxidizes reduced lipoyl groups on E2 and transfers electrons to NAD+, generating NADH | Shared with PDH and OGDH complexes; common E3 module in mitochondrial 2-oxoacid dehydrogenase systems (billington2022genomicandbiochemical pages 1-3, he2026bcaasandrelated pages 8-10) |
| BCKDK | BCKDK | Regulatory kinase associated with the BCKDH complex | Phosphorylates E1α to inhibit BCKDH activity | Major negative regulator of BCAA oxidation; inhibited allosterically by BCKAs such as KIC; pharmacologic inhibition activates BCKDH (du2022theroleof pages 2-4, du2022theroleof pages 6-7, huang2025branchedchainaminoacids pages 2-4) |
| PPM1K | PPM1K | Mitochondrial PP2C-family phosphatase | Dephosphorylates E1α to reactivate BCKDH | Also called PP2Cm; opposes BCKDK to maintain BCAA/BCKA homeostasis and BCKDH flux (huang2025branchedchainaminoacids pages 13-14, du2022theroleof pages 2-4, du2022theroleof pages 6-7, huang2025branchedchainaminoacids pages 2-4) |
Table: This table summarizes the catalytic and regulatory composition of the human BCKDH system, highlighting where BCKDHB fits within the E1 decarboxylase module. It is useful for functional annotation because it distinguishes the core enzyme subunits from the kinase/phosphatase regulators that control pathway activity.
The crystal structure of human BCKDH E1 was determined at 2.7 Å resolution, revealing a tightly packed α₂β₂ heterotetramer (ævarsson2000crystalstructureof pages 1-2). The beta subunit is organized into two similarly sized N-terminal and C-terminal domains, each with an α/β architecture containing a central β-sheet flanked by helices (ævarsson2000crystalstructureof pages 2-4). The tetramer forms four distinct subunit interfaces: α–α′ (burying 3,215 Ų), α–β (1,993 Ų), α–β′ (1,890 Ų), and β–β′ (2,239 Ų). Remarkably, 46% of the beta subunit's accessible surface area is devoted to subunit interactions, underscoring its critical structural role in maintaining the tetrameric assembly (ævarsson2000crystalstructureof pages 5-7).
The beta subunit makes several specific contributions to enzyme function:
ThDP cofactor binding: The active site is located at the α–β′ interface. Key beta subunit residues include Tyr102-β′, which packs against the aminopyrimidine ring of ThDP; Leu74-β′, which provides hydrophobic interactions; and Glu76-β′, which directly coordinates the N1′ atom of the cofactor (ævarsson2000crystalstructureof pages 2-4).
Potassium ion coordination: A K⁺ binding site is located in the beta subunit at the interface with the C-terminal domain of the alpha subunit. This site is coordinated by residues Gly128-β, Leu130-β, Cys178-β, Asp181-β, and Asn183-β, and is critical for structural stability (ævarsson2000crystalstructureof pages 5-7, ævarsson2000crystalstructureof pages 4-5).
Subunit–subunit interactions: His156-β is critical for β–β′ association through hydrophobic packing and hydrogen bonding with the neighboring beta subunit. Asn126-β forms a hydrogen bond network stabilizing local polypeptide conformation (ævarsson2000crystalstructureof pages 7-8).
E2 binding: The beta subunits carry the binding site for the E2 binding domain at or near the twofold axis of the E1 tetramer, enabling assembly of the full multienzyme complex (ævarsson2000crystalstructureof pages 10-12).
The extensive hydrophobic patches at subunit interfaces suggest that E1 assembly requires chaperonin (GroEL/GroES or its mitochondrial equivalent) assistance in vivo (ævarsson2000crystalstructureof pages 5-7).
BCKDHB is synthesized as a precursor protein in the cytoplasm with an N-terminal mitochondrial targeting sequence. Following import into mitochondria and cleavage of the signal peptide, the mature protein assembles into the BCKDH complex within the mitochondrial matrix (weiss2024mitolnccontrolscardiac pages 10-12, du2022theroleof pages 2-4). Subcellular fractionation and MitoTracker co-localization studies confirm the primarily mitochondrial localization of the BCKDH complex (weiss2024mitolnccontrolscardiac pages 10-12).
However, recent work has revealed that BCKDH can also localize to extramitochondrial compartments. In cardiac tissue, proteomic analyses combined with immunoblotting demonstrated that BCKDH localizes not only to mitochondria but also to the endoplasmic reticulum (ER), where it interacts with AMP deaminase 3 (AMPD3) (ogawa2023downregulationofextramitochondrial pages 11-13, ogawa2023downregulationofextramitochondrial pages 9-11). This finding is consistent with observations that related enzymes sharing the E3 subunit with BCKDH (pyruvate dehydrogenase and α-ketoglutarate dehydrogenase) also function in extramitochondrial compartments including the nucleus (ogawa2023downregulationofextramitochondrial pages 9-11). The functional significance of extramitochondrial BCKDH remains an active area of investigation.
The BCAA catabolic pathway is initiated by the reversible transamination of BCAAs to their corresponding BCKAs by branched-chain aminotransferases (BCAT1, cytosolic; BCAT2, mitochondrial) (huang2025branchedchainaminoacids pages 4-5, mei2026branchedchainaminoacids pages 3-5). BCAAs are transported across cell membranes primarily by LAT1 and 4F2hc, and imported into the mitochondria by the carrier SLC25A44 (mei2026branchedchainaminoacids pages 3-5, choi2024theroleof pages 1-2). Within the mitochondrial matrix, BCAT2 catalyzes the first transamination step, producing BCKAs and glutamate from BCAAs and 2-oxoglutarate (huang2025branchedchainaminoacids pages 4-5).
The BCKDH complex then catalyzes the irreversible, rate-limiting oxidative decarboxylation of BCKAs (mei2026branchedchainaminoacids pages 3-5). This commits the carbon skeletons to further catabolism through reactions specific to each amino acid, occurring exclusively in the mitochondrial matrix via pathways analogous to fatty acid oxidation (du2022theroleof pages 2-4). The end products—acetyl-CoA (from leucine and isoleucine) and succinyl-CoA (from valine and isoleucine)—enter the TCA cycle for complete oxidation and ATP production (mei2026branchedchainaminoacids pages 3-5, huang2025branchedchainaminoacids pages 4-5).
Physical interaction between BCAT2 and BCKDH has been demonstrated, and BCAT2 deficiency leads to abolished BCKDH activity, suggesting that substrate channeling or metabolon formation is functionally important (bo2024primaryrolesof pages 11-13).
Tissue-specific differences in BCAA metabolism are well established. BCAT2 is highly expressed in skeletal muscle but low in liver, while BCKDH activity is highest in the liver (bo2024primaryrolesof pages 9-11). Consequently, skeletal muscle is the major site of BCAA transamination, releasing BCKAs into the circulation, while the liver is the primary organ for BCKA oxidation, gluconeogenesis, and ketogenesis (bo2024primaryrolesof pages 9-11, bo2024primaryrolesof pages 11-13). BCAT and BCKDH enzyme activity is also high in skeletal muscle, adipose tissue, and brain (choi2024theroleof pages 2-3).
The activity of the BCKDH complex is tightly regulated through reversible phosphorylation–dephosphorylation of the E1α subunit (BCKDHA), not the E1β subunit directly. BCKDK (branched-chain α-keto acid dehydrogenase kinase) phosphorylates E1α at serine residues 293 and 303, which inactivates the complex (huang2025branchedchainaminoacids pages 13-14, du2022theroleof pages 2-4). PPM1K (also known as PP2Cm), a mitochondrial PP2C-family phosphatase, dephosphorylates E1α to reactivate the complex (huang2025branchedchainaminoacids pages 13-14, huang2025branchedchainaminoacids pages 4-5).
This regulatory cycle is responsive to cellular metabolic status. BCKAs, particularly KIC (the leucine-derived ketoacid), allosterically inhibit BCKDK, thereby promoting BCKDH activation when BCAA concentrations are high (du2022theroleof pages 2-4). Conversely, BCKDK is upregulated under nutrient-excess conditions and suppressed during nutrient scarcity or catabolic stress (huang2025branchedchainaminoacids pages 13-14). The pharmacological BCKDK inhibitor BT2 binds BCKDK and causes its dissociation from the BCKDH complex, leading to dephosphorylation and activation of BCKDH, which increases BCAA oxidation and reduces serum BCAA levels (du2022theroleof pages 6-7).
Transcriptional regulation also modulates BCKDH complex activity. The transcription factor KLF15 upregulates expression of BCKDH subunit genes, including BCKDHB, in cardiac muscle, while PPARγ regulates expression in adipose tissue (choi2024theroleof pages 2-3, ogawa2023downregulationofextramitochondrial pages 11-13).
A novel layer of regulation was recently described by Weiss et al. (2024), who identified a nuclear-encoded long non-coding RNA called mitolnc that localizes to mitochondria and directly interacts with the BCKDH complex to allosterically increase its activity, independent of phosphorylation. Inactivation of mitolnc in mice reduced BCKDH complex activity, causing BCAA accumulation in the heart and cardiac hypertrophy via enhanced mTOR signaling (weiss2024mitolnccontrolscardiac pages 10-12).
Biallelic loss-of-function mutations in BCKDHB cause MSUD type 1B (OMIM #248611), an autosomal recessive inborn error of metabolism characterized by elevated BCAAs and BCKAs in blood and tissues, leading to neurotoxicity, encephalopathy, and, if untreated, death (campanholi2021molecularbasisof pages 1-2, rodriguezpombo2006mutationalspectrumof pages 1-3, billington2022genomicandbiochemical pages 1-3). The disease is named for the characteristic maple syrup odor of affected patients' urine. MSUD can also be caused by mutations in BCKDHA (type 1A), DBT (type II), or DLD.
Multiple population-based studies have identified a broad mutational spectrum in BCKDHB. In a Spanish cohort, 15 of 33 MSUD patients had E1β deficiency, with 14 different BCKDHB sequence variations identified, the most common being c.487G>T (p.Glu163X) found in 6 of 30 disease alleles (rodriguezpombo2006mutationalspectrumof pages 1-3). In a Malaysian cohort, 14 new mutations were identified across BCKDHA, BCKDHB, and DBT, including multiple missense mutations in BCKDHB (p.G101S, p.L194R, p.G66W, p.T365R, p.D88G, p.S261P, p.T273I) predicted to destabilize E1β protein structure (ali2018fourteennewmutations pages 7-8). In a Brazilian cohort, the Pro200Ter variant in BCKDHB was the most prevalent pathogenic mutation (19% of patients), and 9 of 12 classical phenotype patients had the E1β genetic subtype (margutti2020maplesyrupurine pages 2-4). An Egyptian study identified four BCKDHB variants including a biallelic duplication affecting exons 2–6 (OpenTargets Search: -BCKDHB). Chinese patient studies identified homozygous deletions (c.372_377del6 and c.713delC) causing frameshifts resulting in non-functional or truncated proteins (yang2012analysisofgene pages 6-6).
Structural analysis of MSUD mutations using the crystal structure explains their pathogenic mechanisms, including disruption of cofactor binding sites, potassium ion coordination, hydrophobic core packing, and subunit interfaces (ævarsson2000crystalstructureof pages 1-2, ævarsson2000crystalstructureof pages 7-8). Clinical phenotypes of MSUD include classic (most severe, neonatal onset), intermediate, intermittent, and thiamine-responsive forms, depending on residual enzyme activity (campanholi2021molecularbasisof pages 1-2).
OpenTargets database analysis confirms strong disease associations between BCKDHB and MSUD (association score 0.86), MSUD type 1B (0.79), hereditary disease (0.86), and skeletal abnormalities (0.45) (OpenTargets Search: -BCKDHB).
Beyond MSUD, impaired BCKDH complex activity has been implicated in numerous metabolic disorders. Elevated plasma BCAAs are strongly associated with insulin resistance, type 2 diabetes, obesity, and cardiovascular disease (mei2026branchedchainaminoacids pages 3-5, huang2025branchedchainaminoacids pages 2-4). In genetically obese mice, rate-limiting BCKDH deficiency accompanies systemic suppression of BCAA catabolic genes, and restoring BCAA catabolic flux with BCKDK inhibitors markedly attenuates insulin resistance (du2022theroleof pages 6-7). In heart failure, impaired BCKDH activity leads to BCAA accumulation and cardiac dysfunction; pharmacological activation of BCKDH through BT2 decreases cardiac BCAA levels and improves heart function (ogawa2023downregulationofextramitochondrial pages 11-13). Furthermore, dysregulated BCAA metabolism has been implicated in cancer progression, where BCKDH activity may promote or suppress tumorigenesis in a context-dependent manner (he2026bcaasandrelated pages 8-10).
BCKDHB encodes the beta subunit of the E1 decarboxylase component of the mitochondrial BCKDH multienzyme complex, which catalyzes the irreversible oxidative decarboxylation of branched-chain alpha-ketoacids—the rate-limiting step in BCAA catabolism. The beta subunit is essential for ThDP cofactor binding at the α–β′ interface, potassium ion coordination, structural integrity of the α₂β₂ heterotetramer, and interaction with the E2 core of the complex. The BCKDH complex functions primarily in the mitochondrial matrix, where it commits BCAA-derived carbon skeletons to oxidative catabolism producing acetyl-CoA and succinyl-CoA for the TCA cycle. Complex activity is regulated by BCKDK-mediated phosphorylation (inactivation) and PPM1K-mediated dephosphorylation (activation) of the E1α subunit, as well as by allosteric mechanisms and, recently identified, lncRNA-mediated regulation. Loss-of-function mutations in BCKDHB cause MSUD type 1B, while broader impairment of BCKDH activity is implicated in insulin resistance, heart failure, and cancer metabolism.
References
(ævarsson2000crystalstructureof pages 1-2): Arnthor Ævarsson, Jacinta L Chuang, R Max Wynn, Stewart Turley, David T Chuang, and Wim GJ Hol. Crystal structure of human branched-chain α-ketoacid dehydrogenase and the molecular basis of multienzyme complex deficiency in maple syrup urine disease. Structure, 8:277-291, Mar 2000. URL: https://doi.org/10.1016/s0969-2126(00)00105-2, doi:10.1016/s0969-2126(00)00105-2. This article has 218 citations and is from a domain leading peer-reviewed journal.
(billington2022genomicandbiochemical pages 1-3): Charles J. Billington, Kimberly A. Chapman, Eyby Leon, Beatrix W. Meltzer, Seth I. Berger, Matthew Olson, Robert A. Figler, Steve A. Hoang, Cui Wanxing, Brian R. Wamhoff, M. Sol Collado, and Kristina Cusmano‐Ozog. Genomic and biochemical analysis of repeatedly observed variants in dbt in individuals with maple syrup urine disease of central american ancestry. American Journal of Medical Genetics. Part a, 188:2738-2749, Jul 2022. URL: https://doi.org/10.1002/ajmg.a.62893, doi:10.1002/ajmg.a.62893. This article has 6 citations and is from a peer-reviewed journal.
(ævarsson2000crystalstructureof pages 7-8): Arnthor Ævarsson, Jacinta L Chuang, R Max Wynn, Stewart Turley, David T Chuang, and Wim GJ Hol. Crystal structure of human branched-chain α-ketoacid dehydrogenase and the molecular basis of multienzyme complex deficiency in maple syrup urine disease. Structure, 8:277-291, Mar 2000. URL: https://doi.org/10.1016/s0969-2126(00)00105-2, doi:10.1016/s0969-2126(00)00105-2. This article has 218 citations and is from a domain leading peer-reviewed journal.
(ævarsson2000crystalstructureof pages 2-4): Arnthor Ævarsson, Jacinta L Chuang, R Max Wynn, Stewart Turley, David T Chuang, and Wim GJ Hol. Crystal structure of human branched-chain α-ketoacid dehydrogenase and the molecular basis of multienzyme complex deficiency in maple syrup urine disease. Structure, 8:277-291, Mar 2000. URL: https://doi.org/10.1016/s0969-2126(00)00105-2, doi:10.1016/s0969-2126(00)00105-2. This article has 218 citations and is from a domain leading peer-reviewed journal.
(ævarsson2000crystalstructureof pages 4-5): Arnthor Ævarsson, Jacinta L Chuang, R Max Wynn, Stewart Turley, David T Chuang, and Wim GJ Hol. Crystal structure of human branched-chain α-ketoacid dehydrogenase and the molecular basis of multienzyme complex deficiency in maple syrup urine disease. Structure, 8:277-291, Mar 2000. URL: https://doi.org/10.1016/s0969-2126(00)00105-2, doi:10.1016/s0969-2126(00)00105-2. This article has 218 citations and is from a domain leading peer-reviewed journal.
(du2022theroleof pages 1-2): Chuang Du, Wen-Jie Liu, Jing Yang, Shan-Shan Zhao, and Hui-Xin Liu. The role of branched-chain amino acids and branched-chain α-keto acid dehydrogenase kinase in metabolic disorders. Frontiers in Nutrition, Jul 2022. URL: https://doi.org/10.3389/fnut.2022.932670, doi:10.3389/fnut.2022.932670. This article has 98 citations.
(du2022theroleof pages 2-4): Chuang Du, Wen-Jie Liu, Jing Yang, Shan-Shan Zhao, and Hui-Xin Liu. The role of branched-chain amino acids and branched-chain α-keto acid dehydrogenase kinase in metabolic disorders. Frontiers in Nutrition, Jul 2022. URL: https://doi.org/10.3389/fnut.2022.932670, doi:10.3389/fnut.2022.932670. This article has 98 citations.
(ogawa2023downregulationofextramitochondrial pages 11-13): Toshifumi Ogawa, Hidemichi Kouzu, Arata Osanami, Yuki Tatekoshi, Tatsuya Sato, Atsushi Kuno, Yugo Fujita, Shoya Ino, Masaki Shimizu, Yuki Toda, Wataru Ohwada, Toshiyuki Yano, Masaya Tanno, Takayuki Miki, and Tetsuji Miura. Downregulation of extramitochondrial bckdh and its uncoupling from amp deaminase in type 2 diabetic oletf rat hearts. Physiological Reports, Feb 2023. URL: https://doi.org/10.14814/phy2.15608, doi:10.14814/phy2.15608. This article has 15 citations and is from a peer-reviewed journal.
(ogawa2023downregulationofextramitochondrial pages 9-11): Toshifumi Ogawa, Hidemichi Kouzu, Arata Osanami, Yuki Tatekoshi, Tatsuya Sato, Atsushi Kuno, Yugo Fujita, Shoya Ino, Masaki Shimizu, Yuki Toda, Wataru Ohwada, Toshiyuki Yano, Masaya Tanno, Takayuki Miki, and Tetsuji Miura. Downregulation of extramitochondrial bckdh and its uncoupling from amp deaminase in type 2 diabetic oletf rat hearts. Physiological Reports, Feb 2023. URL: https://doi.org/10.14814/phy2.15608, doi:10.14814/phy2.15608. This article has 15 citations and is from a peer-reviewed journal.
(weiss2024mitolnccontrolscardiac pages 10-12): Maria Weiss, Sara Hettrich, Theresa Hofmann, Salma Hachim, Stefan Günther, Thomas Braun, and Thomas Boettger. Mitolnc controls cardiac bcaa metabolism and heart hypertrophy by allosteric activation of bckdh. Nucleic Acids Research, 52:6629-6646, Apr 2024. URL: https://doi.org/10.1093/nar/gkae226, doi:10.1093/nar/gkae226. This article has 11 citations and is from a highest quality peer-reviewed journal.
(ævarsson2000crystalstructureof pages 10-12): Arnthor Ævarsson, Jacinta L Chuang, R Max Wynn, Stewart Turley, David T Chuang, and Wim GJ Hol. Crystal structure of human branched-chain α-ketoacid dehydrogenase and the molecular basis of multienzyme complex deficiency in maple syrup urine disease. Structure, 8:277-291, Mar 2000. URL: https://doi.org/10.1016/s0969-2126(00)00105-2, doi:10.1016/s0969-2126(00)00105-2. This article has 218 citations and is from a domain leading peer-reviewed journal.
(margutti2020maplesyrupurine pages 2-4): Ana Vitoria Barban Margutti, Wilson Araújo Silva, Daniel Fantozzi Garcia, Greice Andreotti de Molfetta, Adriana Aparecida Marques, Tatiana Amorim, Vânia Mesquita Gadelha Prazeres, Raquel Tavares Boy da Silva, Irene Kazue Miura, João Seda Neto, Emerson de Santana Santos, Mara Lúcia Schmitz Ferreira Santos, Charles Marques Lourenço, Tássia Tonon, Fernanda Sperb-Ludwig, Carolina Fischinger Moura de Souza, Ida Vanessa Döederlein Schwartz, and José Simon Camelo. Maple syrup urine disease in brazilian patients: variants and clinical phenotype heterogeneity. Orphanet Journal of Rare Diseases, Nov 2020. URL: https://doi.org/10.1186/s13023-020-01590-7, doi:10.1186/s13023-020-01590-7. This article has 18 citations and is from a peer-reviewed journal.
(campanholi2021molecularbasisof pages 1-2): Diana Ruffato Resende Campanholi, Ana Vitoria Barban Margutti, Wilson A. Silva, Daniel F. Garcia, Greice A. Molfetta, Adriana A. Marques, Ida Vanessa Döederlein Schwartz, V. Cornejo, Valerie Hamilton, Gabriela Castro, Fernanda Sperb‐Ludwig, Ester S. Borges, and José S. Camelo. Molecular basis of various forms of maple syrup urine disease in chilean patients. Molecular Genetics & Genomic Medicine, May 2021. URL: https://doi.org/10.1002/mgg3.1616, doi:10.1002/mgg3.1616. This article has 10 citations and is from a peer-reviewed journal.
(rodriguezpombo2006mutationalspectrumof pages 1-3): Pilar Rodríguez-Pombo, Rosa Navarrete, Begoña Merinero, Paulino Gómez-Puertas, and Magdalena Ugarte. Mutational spectrum of maple syrup urine disease in spain. Human Mutation, 27:715-715, Jul 2006. URL: https://doi.org/10.1002/humu.9428, doi:10.1002/humu.9428. This article has 69 citations and is from a domain leading peer-reviewed journal.
(OpenTargets Search: -BCKDHB): Open Targets Query (-BCKDHB, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(huang2025branchedchainaminoacids pages 13-14): Hui-Yu Huang, Shu-Ping Tsao, and Tu-Hsueh Yeh. Branched-chain amino acids in parkinson’s disease: molecular mechanisms and therapeutic potential. International Journal of Molecular Sciences, 26:6992, Jul 2025. URL: https://doi.org/10.3390/ijms26146992, doi:10.3390/ijms26146992. This article has 13 citations.
(du2022theroleof pages 6-7): Chuang Du, Wen-Jie Liu, Jing Yang, Shan-Shan Zhao, and Hui-Xin Liu. The role of branched-chain amino acids and branched-chain α-keto acid dehydrogenase kinase in metabolic disorders. Frontiers in Nutrition, Jul 2022. URL: https://doi.org/10.3389/fnut.2022.932670, doi:10.3389/fnut.2022.932670. This article has 98 citations.
(mei2026branchedchainaminoacids pages 3-5): Jie Mei, Fu-yuan Yang, and Quan Gong. Branched-chain amino acids and insulin resistance in type 2 diabetes: from metabolic dysregulation to therapeutic targets. Frontiers in Endocrinology, Feb 2026. URL: https://doi.org/10.3389/fendo.2025.1643231, doi:10.3389/fendo.2025.1643231. This article has 4 citations.
(huang2025branchedchainaminoacids pages 4-5): Hui-Yu Huang, Shu-Ping Tsao, and Tu-Hsueh Yeh. Branched-chain amino acids in parkinson’s disease: molecular mechanisms and therapeutic potential. International Journal of Molecular Sciences, 26:6992, Jul 2025. URL: https://doi.org/10.3390/ijms26146992, doi:10.3390/ijms26146992. This article has 13 citations.
(he2026bcaasandrelated pages 8-10): Binfan He, Lingxi Li, Ye Liu, Mengmeng Hao, Ling Zhang, and Rongzhang He. Bcaas and related metabolic enzymes: partners in crime driving tumor development. Frontiers in Cell and Developmental Biology, Feb 2026. URL: https://doi.org/10.3389/fcell.2026.1748587, doi:10.3389/fcell.2026.1748587. This article has 0 citations.
(huang2025branchedchainaminoacids pages 2-4): Hui-Yu Huang, Shu-Ping Tsao, and Tu-Hsueh Yeh. Branched-chain amino acids in parkinson’s disease: molecular mechanisms and therapeutic potential. International Journal of Molecular Sciences, 26:6992, Jul 2025. URL: https://doi.org/10.3390/ijms26146992, doi:10.3390/ijms26146992. This article has 13 citations.
(ævarsson2000crystalstructureof pages 5-7): Arnthor Ævarsson, Jacinta L Chuang, R Max Wynn, Stewart Turley, David T Chuang, and Wim GJ Hol. Crystal structure of human branched-chain α-ketoacid dehydrogenase and the molecular basis of multienzyme complex deficiency in maple syrup urine disease. Structure, 8:277-291, Mar 2000. URL: https://doi.org/10.1016/s0969-2126(00)00105-2, doi:10.1016/s0969-2126(00)00105-2. This article has 218 citations and is from a domain leading peer-reviewed journal.
(choi2024theroleof pages 1-2): Byeong Hun Choi, Seunghoon Hyun, and Seung-Hoi Koo. The role of bcaa metabolism in metabolic health and disease. Experimental & Molecular Medicine, 56:1552-1559, Jul 2024. URL: https://doi.org/10.1038/s12276-024-01263-6, doi:10.1038/s12276-024-01263-6. This article has 130 citations and is from a peer-reviewed journal.
(bo2024primaryrolesof pages 11-13): Tomoki Bo and Junichi Fujii. Primary roles of branched chain amino acids (bcaas) and their metabolism in physiology and metabolic disorders. Molecules, 30:56, Dec 2024. URL: https://doi.org/10.3390/molecules30010056, doi:10.3390/molecules30010056. This article has 61 citations.
(bo2024primaryrolesof pages 9-11): Tomoki Bo and Junichi Fujii. Primary roles of branched chain amino acids (bcaas) and their metabolism in physiology and metabolic disorders. Molecules, 30:56, Dec 2024. URL: https://doi.org/10.3390/molecules30010056, doi:10.3390/molecules30010056. This article has 61 citations.
(choi2024theroleof pages 2-3): Byeong Hun Choi, Seunghoon Hyun, and Seung-Hoi Koo. The role of bcaa metabolism in metabolic health and disease. Experimental & Molecular Medicine, 56:1552-1559, Jul 2024. URL: https://doi.org/10.1038/s12276-024-01263-6, doi:10.1038/s12276-024-01263-6. This article has 130 citations and is from a peer-reviewed journal.
(ali2018fourteennewmutations pages 7-8): Ernie Zuraida Ali and Lock-Hock Ngu. Fourteen new mutations of bckdha, bckdhb and dbt genes associated with maple syrup urine disease (msud) in malaysian population. Dec 2018. URL: https://doi.org/10.1016/j.ymgmr.2018.08.006, doi:10.1016/j.ymgmr.2018.08.006. This article has 43 citations.
(yang2012analysisofgene pages 6-6): Nan Yang, Lianshu Han, Xuefan Gu, Jun Ye, Wenjuan Qiu, Huiwen Zhang, Zhuwen Gong, and Yafen Zhang. Analysis of gene mutations in chinese patients with maple syrup urine disease. Molecular genetics and metabolism, 106 4:412-8, Aug 2012. URL: https://doi.org/10.1016/j.ymgme.2012.05.023, doi:10.1016/j.ymgme.2012.05.023. This article has 45 citations and is from a peer-reviewed journal.